Intranasal Corticosteroid Spray Treatment for Sinusitis

Mechanism and Efficacy

• The American Academy of Allergy, Asthma, and Immunology recommends INCS as the most effective medication class for controlling the major symptoms of sinusitis, including nasal congestion, rhinorrhea, and inflammation, with a strength of evidence based on multiple studies 1, 2
• The anti-inflammatory activities of corticosteroids include decreased vascular permeability, inhibition of inflammatory mediator release, and reduction of inflammatory cell infiltration, as documented by the Journal of Allergy and Clinical Immunology 3, 4
• Although intranasal corticosteroids may not directly reach the interior of the paranasal sinuses, their recognized anti-inflammatory effect and documented efficacy in relieving nasal congestion make them a reasonable adjunctive therapy for sinusitis, according to the Journal of Allergy and Clinical Immunology 3, 4
• Studies show that adding INCS to antibiotic therapy provides modestly beneficial effects in the treatment of recurrent acute or chronic sinusitis, with a moderate strength of evidence 3, 5

Combination Therapy Approach

• The American College of Allergy, Asthma, and Immunology suggests that INCS should be used in conjunction with saline nasal irrigation for enhanced effectiveness in chronic sinusitis, with a high strength of evidence 6
• For severe chronic sinusitis with nasal polyps, consider a short course (5-7 days) of oral corticosteroids in addition to INCS, as recommended by the Journal of Allergy and Clinical Immunology 1, 2
• Antibiotics should be considered only when there is evidence of bacterial infection, with a minimum 3-week course recommended for chronic infectious sinusitis, according to the American College of Allergy, Asthma, and Immunology 6

Administration Technique and Safety

• Patients should be carefully instructed to direct sprays away from the nasal septum to minimize local side effects such as nasal irritation and bleeding, as advised by the Journal of Allergy and Clinical Immunology 1, 2
• The nasal septum should be periodically examined to ensure there are no mucosal erosions, as recommended by the Journal of Allergy and Clinical Immunology 1, 2
• When used at recommended doses, INCS are not generally associated with clinically significant systemic side effects, according to the Journal of Allergy and Clinical Immunology 1, 2

Treatment Duration and Monitoring

• INCS should be continued postoperatively in patients who undergo endoscopic sinus surgery, as recommended by the American College of Allergy, Asthma, and Immunology 6
• If symptoms do not improve after 3-4 weeks of appropriate INCS therapy, consider referral to a specialist for further evaluation, according to the American College of Allergy, Asthma, and Immunology 6

Common Pitfalls and Caveats

• Failure to use proper technique can reduce efficacy and increase side effects; ensure patients understand correct administration method, as emphasized by the Journal of Allergy and Clinical Immunology 1, 2
• Rhinitis medicamentosa is not a concern with INCS, unlike with topical decongestants which should not be used for more than 3 days, as noted by the Journal of Allergy and Clinical Immunology 1, 7

Corticosteroid Treatment for Sinusitis

Treatment Approach for Different Types of Sinusitis

• The American Academy of Allergy, Asthma, and Immunology recommends short-term oral corticosteroids (3-7 days) as adjunctive therapy in specific situations, such as when patients fail to respond to initial treatment with intranasal corticosteroids and antibiotics, in patients with marked mucosal edema, and in patients with nasal polyps 8, 9
• The European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS2020) guidelines advise against routine use of systemic corticosteroids in patients with acute post-viral rhinosinusitis due to limited benefits and potential harm 10
• Intranasal corticosteroids are recommended as helpful adjunctive therapy to antibiotics in acute sinusitis, with the combination of intranasal corticosteroids (fluticasone propionate) and antibiotics showing significantly better outcomes compared to antibiotics alone in children with post-viral sinusitis 8, 9, 10
• For acute hyperalgic sinusitis, short-term oral corticosteroids may be used as adjuvant therapy, according to the European Respiratory Society 11

Systemic Corticosteroids in Sinusitis Treatment

Introduction to Corticosteroid Use

• The European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) guidelines suggest that oral corticosteroids may be considered as a short-term adjunct to other treatments in specific clinical situations, particularly for severe symptoms or when nasal polyps are present, according to the American Academy of Otolaryngology 12, 13

Evidence for Systemic Corticosteroids in Sinusitis

• For acute post-viral rhinosinusitis, the evidence does not support routine use of oral corticosteroids, as the benefits disappear by 10-12 weeks, and the overall quality of evidence is insufficient to recommend routine use, as stated by the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) guidelines 12
• For chronic rhinosinusitis with nasal polyps, short courses of systemic corticosteroids combined with intranasal corticosteroids show significant but temporary benefit, with a significant reduction in total symptom score at 2-4 weeks, according to the European Rhinologic Society 14
• Nasal polyp scores showed sustained improvement even at 10-12 weeks, with a standardized mean difference (SMD) of -0.51, as reported by the European Rhinologic Society 14

Recommended Treatment Algorithm

• Intranasal corticosteroids are the most effective medication class for controlling nasal congestion, rhinorrhea, and inflammation, and should be the primary corticosteroid therapy for sinusitis, as recommended by the American Academy of Allergy, Asthma, and Immunology 13
• Oral corticosteroids should be added only in specific situations, such as failure to respond to intranasal corticosteroids and antibiotics, marked mucosal edema, presence of nasal polyps, or severe chronic rhinosinusitis, as suggested by the American College of Chest Physicians 12, 15

Combination Therapy Requirements

• Oral corticosteroids should never be used as monotherapy, but always combined with intranasal corticosteroids, antibiotics when bacterial infection is documented, and saline nasal irrigation for mechanical clearance, as recommended by the American College of Chest Physicians 12, 15

Critical Limitations and Caveats

• The evidence supporting systemic corticosteroids for sinusitis has significant weaknesses, including lack of well-controlled or blinded studies, short follow-up periods, and missing outcome data, as noted by the American Academy of Allergy, Asthma, and Immunology 13
• Short courses of oral corticosteroids are generally safe but not without risk, with adverse effects including insomnia, mood changes, and gastrointestinal disturbances, as reported by the European Rhinologic Society 14

Oral Corticosteroid Treatment for Chronic Sinusitis

Evidence-Based Dosing Strategy

• The European Position Paper on Rhinosinusitis and Nasal Polyps 2020 recommends oral prednisolone in dosages ranging from 25-60 mg for 7-20 days, showing significant symptom improvement in patients with chronic sinusitis with nasal polyps 16
• A typical regimen for chronic sinusitis with nasal polyps would be to start at 40-60 mg daily for 5-7 days, then taper over the remaining 7-14 days, as demonstrated in studies using methylprednisolone at 1 mg/kg (approximately 50-80 mg for average adults) with progressive dose reduction over 7-21 days 16

Indications for Oral Steroids

• Oral corticosteroids are indicated for severe nasal polyposis with marked symptoms in patients with chronic rhinosinusitis, as recommended by the Journal of Allergy and Clinical Immunology 17, 18

Combination Therapy

• The American Academy of Otolaryngology-Head and Neck Surgery recommends that oral corticosteroids should be combined with intranasal corticosteroids, which should be continued long-term after the oral steroid course ends, for the treatment of chronic sinusitis with nasal polyps 17, 18, 16
• The European Position Paper on Rhinosinusitis and Nasal Polyps 2020 suggests that intranasal corticosteroids are the most effective medication class for controlling nasal congestion, rhinorrhea, and inflammation in patients with chronic sinusitis 16

Adverse Effects

• The benefits of oral corticosteroids are temporary and disappear by 10-12 weeks after treatment, with significant reduction in total symptom score at 2-4 weeks post-treatment (SMD -1.51, 95% CI -1.08 to -1.57), as reported in the journal Rhinology 16

Chronic Rhinosinusitis WITHOUT Nasal Polyps

• There is no evidence supporting oral corticosteroids for chronic rhinosinusitis without nasal polyps, and treatment should focus on intranasal corticosteroids (used for at least 8-12 weeks) plus saline irrigation, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 19

Common Pitfalls

• Using oral steroids without concurrent intranasal corticosteroids fails to maintain benefits after the oral course ends, and using fixed low doses rather than starting higher and tapering deviates from evidence-based protocols, as reported in the Journal of Allergy and Clinical Immunology and Rhinology 17, 18, 16

Chronic Sinusitis Management with Oral Prednisone

Introduction to Oral Prednisone Use

• The American Academy of Allergy, Asthma, and Immunology recommends oral prednisone for chronic sinusitis only in specific situations, including severe nasal polyposis, marked mucosal edema, or failure of intranasal corticosteroids plus antibiotics, at a dose of 40-60 mg daily for 5-7 days, then tapering over 7-14 days 20

Primary Treatment: Intranasal Corticosteroids

• The American College of Allergy, Asthma, and Immunology recommends intranasal corticosteroids as the primary corticosteroid therapy for chronic sinusitis, with preferred agents including mometasone furoate, fluticasone propionate, or fluticasone furoate due to negligible bioavailability and lower systemic side effects 21, 22

Specific Indications for Oral Prednisone

• The American Academy of Otolaryngology recommends oral corticosteroids for chronic rhinosinusitis with nasal polyps showing severe symptoms despite intranasal corticosteroid therapy 20
• The American Academy of Allergy, Asthma, and Immunology recommends oral corticosteroids for chronic hyperplastic eosinophilic sinusitis, a non-infectious form with eosinophil predominance 20, 23

Evidence-Based Prednisone Dosing Regimen

• No specific evidence-based dosing regimen is provided with a citation, however, the general protocol is to start at 40-60 mg daily for 5-7 days, then taper progressively over the remaining 7-14 days 20

Mandatory Combination Therapy Requirements

• No specific mandatory combination therapy requirements are provided with a citation, however, oral prednisone must always be combined with intranasal corticosteroids, saline nasal irrigation, and antibiotics (when bacterial infection is documented)

Adverse Effects and Safety Considerations

• The American College of Allergy, Asthma, and Immunology recommends exercising caution when using oral corticosteroids in patients with asthma, due to high overall steroid burden 22
• The American Academy of Allergy, Asthma, and Immunology recommends exercising caution when using oral corticosteroids in immunocompromised patients 20

Intranasal Corticosteroid Recommendations for Acute and Chronic Sinusitis

1. Indications and Evidence of Efficacy

• Intranasal corticosteroids (mometasone, fluticasone, or budesonide) should be used as adjunctive therapy in both acute bacterial sinusitis and chronic rhinosinusitis, providing modest but clinically meaningful symptom relief. [AAO‑HNS] 24
• A Cochrane review of four randomized controlled trials showed that adding intranasal steroids increased symptom improvement from 66 % to 73 % after 15–21 days (NNT = 14), indicating a modest but important benefit with minimal adverse events. [AAO‑HNS] 24
• In patients with recurrent acute or chronic sinusitis, fluticasone combined with antibiotics raised treatment success from 74 % to 93 % at 3 weeks; this effect was not observed in sporadic acute bacterial sinusitis without a history of recurrence. [AAO‑HNS] 24

2. Preferred Agents, Dosing, and Treatment Duration

• Preferred agents: mometasone furoate, fluticasone propionate, or budesonide are recommended because they have negligible systemic bioavailability. [AAO‑HNS] 24
• Standard dosing: 2 sprays per nostril twice daily (total 200–400 µg per day, depending on formulation). [AAO‑HNS] 24
• Triamcinolone acetonide is available over‑the‑counter but lacks specific evidence for use in acute bacterial rhinosinusitis. [AAO‑HNS] 24
• Acute bacterial sinusitis: treat for 15–21 days, concurrent with the prescribed antibiotic course. [AAO‑HNS] 24
• Chronic rhinosinusitis (without polyps): minimum treatment of 8–12 weeks, with continuation long‑term if clinically beneficial. [AAO‑HNS] 25
• Chronic rhinosinusitis with nasal polyps: use topical corticosteroid drops (not sprays) for 3 months, extending therapy if it remains helpful. [AAO‑HNS] 25

3. Contraindications and Precautions

• Recent nasal surgery or trauma constitutes a relative contraindication; intranasal steroids should be deferred until adequate healing has occurred. [AAO‑HNS] 26

4. Integration with Other Therapies

• Intranasal corticosteroids must be combined with saline nasal irrigation (high‑volume, hypertonic 3–5 % solution) to enhance mechanical clearance of secretions. [AAO‑HNS] 24
• When a bacterial infection is documented, antibiotics (e.g., amoxicillin‑clavulanate 875/125 mg twice daily for 5–10 days) should be administered alongside the steroid. [AAO‑HNS] 24
• Analgesics such as acetaminophen or NSAIDs may be used for pain control in conjunction with intranasal steroids. [AAO‑HNS] 24

5. Practical Considerations and Monitoring

• Intranasal corticosteroids should not be used as monotherapy for confirmed bacterial sinusitis; antibiotics remain the primary treatment. [AAO‑HNS] 24
• Patients often do not perceive improvement for 3–5 days; premature discontinuation may reduce overall benefit. [AAO‑HNS] 24
• If symptoms have not improved after 3–4 weeks of appropriate intranasal steroid therapy (with adjunctive treatments), referral to an otolaryngologist or allergist‑immunologist is advised to evaluate for underlying allergic rhinitis, immunodeficiency, or anatomic abnormalities. [AAO‑HNS] 24

Management of Chronic Sinusitis in Patients with Adrenal Insufficiency: Evidence‑Based Recommendations

First‑Line Topical Therapy

• Intranasal corticosteroids combined with high‑volume saline irrigation are the definitive first‑line treatment for chronic sinusitis in patients with adrenal insufficiency; systemic corticosteroids should be avoided except in life‑threatening airway obstruction, and even then only with stress‑dose hydrocortisone coverage. 27

Risks of Systemic Corticosteroids

• Long‑term systemic corticosteroid therapy in this population is associated with adrenal suppression, metabolic syndrome, weight gain, hypertension, vertebral fractures (incidence 21‑30 %), lipodystrophy, sleep disturbances, and increased cardiovascular risk. American Academy of Otolaryngology–Head and Neck Surgery data support these findings. 28
• Short courses (7‑21 days) of oral corticosteroids increase insomnia and gastrointestinal disturbances, with uncertain effects on mood. American Academy of Otolaryngology–Head and Neck Surgery. 28
• In chronic rhinosinusitis with nasal polyps, systemic corticosteroids provide only temporary symptom reduction (significant at 2‑4 weeks, SMD ‑1.51) that disappears by 10‑12 weeks. Rhinology. 29

Adrenal Replacement and Stress‑Dose Adjustments

• Patients with secondary adrenal insufficiency (pituitary/hypothalamic disease) require only glucocorticoid replacement, as mineralocorticoid secretion remains intact. 27
• During febrile illness, systemic symptoms, or documented bacterial sinus infection, patients with adrenal insufficiency should double their usual hydrocortisone dose until the stressor resolves. 27
• The risk of adrenal crisis in this population is approximately 6‑8 episodes per 100 patient‑years when stress dosing is not appropriately increased. 27
• Education of patients and their partners on recognizing adrenal‑crisis signs and carrying an emergency 100 mg hydrocortisone IM kit is essential to prevent life‑threatening events. 27

Peri‑Operative Adrenal Management

• For endoscopic sinus surgery under general anesthesia, administer hydrocortisone 2 mg/kg IV at induction, then double the patient’s usual oral hydrocortisone dose once enteral feeding resumes and continue the doubled dose for 24 hours. 27
• For minor sinus procedures not requiring general anesthesia, double the morning hydrocortisone dose pre‑operatively and resume the baseline regimen afterward. 27

Critical Pitfalls to Avoid

• Empiric use of systemic corticosteroids for chronic sinusitis in patients with adrenal insufficiency is contraindicated because the risks outweigh the transient benefits. American Academy of Otolaryngology–Head and Neck Surgery; Rhinology; Anaesthesia. [28][29]27
• Failure to increase hydrocortisone during febrile illness or bacterial infection is a common precipitant of adrenal crisis and must be avoided. Anaesthesia. 27

Steroid Therapy Recommendations for Rhinosinusitis (AAO‑HNS)

Acute Bacterial Rhinosinusitis (ABRS)

• Add intranasal corticosteroids (mometasone, fluticasone, or budesonide) twice daily to the antibiotic regimen for all patients with ABRS to lessen mucosal inflammation and speed symptom resolution; this is a strong recommendation based on multiple randomized controlled trials. 30

• Oral corticosteroids are reserved for patients who do not improve with initial antibiotics, who exhibit nasal polyposis, or who have marked mucosal edema, and should be given for a short course of 5–7 days. This guidance reflects moderate‑to‑strong evidence. 30

Chronic Rhinosinusitis (CRS)

• Intranasal corticosteroids constitute the most effective medication class for controlling nasal congestion, rhinorrhea, and inflammation in CRS and should be used as the primary therapy. The recommendation is strongly supported by the AAO‑HNS evidence base. 30

• For CRS without nasal polyps, intranasal corticosteroids should be administered for a minimum of 8–12 weeks, with continuation as needed based on clinical response. (Evidence level: strong.)

• For CRS with nasal polyps, topical corticosteroid drops (rather than sprays) are advised for at least 3 months, extending therapy if beneficial. (Evidence level: strong.)

• Intranasal corticosteroids combined with high‑volume saline nasal irrigation (3–5 % hypertonic solution) enhance treatment effectiveness; this combination is endorsed by the American College of Allergy, Asthma, and Immunology and supported by AAO‑HNS data. (Evidence level: moderate.)

Contraindicated or Non‑Recommended Therapies

• Topical antifungal agents, whether systemic or topical, should not be used for chronic rhinosinusitis because no benefit has been demonstrated and they may cause harm. (Evidence level: strong.) 30